The technique deploys several strategies to reduce cancer risk. It is being evaluated in mouse models but researchers are already looking ahead to human studies.
Standard treatment for those with type 1 diabetes (T1D) is insulin injections, since the patient’s own immune systems has for some reason destroyed the beta cells that produce it in the pancreas, thus regulating blood sugar.
But what if something else could do the work of beta cells, and free patients from all those injections? Scientists presenting a technique at the 54th Annual European Society for Pediatric Endocrinology believe they have found such a method.
Researchers from the Universite Catholique de Louvain in Belgium, led by Philippe Lysy, MD (a former postdoctoral fellow at Joslin Diabetes Center in Boston), had previously shown that human pancreatic duct-derived cells, or HDDCs, were a potential source of replacement cells, since they are progenitor cells.
The research team reprogrammed the HDDCs to behave like beta cells and secrete insulin, when responding to glucose. To do this, they used messenger RNA of a transcription factor MAFA, a protein that controls which genes are turned on or off in the genome. The mRNA is converted to protein before binding to cellular DNA, which allows the behavioral change of the HDDC to happen at the cellular level. This is done to avoid genetic mutations that could later cause cancer.
So far, the team has been able to transplant these converted cells in mouse models, and they await results on how well the insulin secretion is working.
A significant benefit of this technique is its use of adult cells instead of stem cells, which additionally avoid cancer risk.
While group awaits results from the mouse model, it is also producing batches of cells for future studies with human patients, Lysy said in a statement.
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Balancing Care Access and Fragmentation for Better Outcomes in Veterans With Diabetes
April 22nd 2021The authors of a study in the April 2021 issue of The American Journal of Managed Care® discuss the possible reasons behind the link between care fragmentation and hospitalizations in veterans with diabetes, as well as potential opportunities to address disjointed care in the context of the widespread telehealth uptake seen during the COVID-19 pandemic.
Listen